The report provides a detailed understanding and analysis of how and why companies enter into partner agreements. These businesses are generally multi-compatible, starting with collaborative research and development, and go to commercializing the results. The report details the latest companion diagnostic agreements announced in life sciences since 2010. The report guides the reader through a global journal Companion Diagnostics Deal Trends, Key Player, top deal values and deal finances, in order to understand how, why and under what conditions the company`s companies enter into partnership agreements. The report presents the benchmarks for companion diagnostic companies, which list based on engine value, advances, milestone payments and royalties, allowing readers to analyze and compare the financial value of transactions. The middle part of the report examines the main dealmakers in the companion diagnostics partnership; Both the values of deal leaders and the most active companion-dealmakers companies must allow the reader to see who succeeds in this dynamic dealmaking market. One of the main strengths of the report is that more than 450 sets of online agreements of actual companion diagnostic agreements, as revealed by the deal parts, are included towards the end of the report in a directory format – according to the company A-Z, stage of development, type of deal, therapeutic support and type of technology – it is easy to reference. Each deal registration in the report is linked to an online version of the agreement via a web link. In addition, the documents contain, when available, contractual documents submitted by companies and their partners to the Securities Exchange Commission. While many companies are looking for payment terms details, the problem is how payments are triggered – contract documents provide this information where press releases and databases do not. The first chapters of this report provide an overview of Companion Diagnostics` dealmaking. About Thermo Fisher ScientificThermo Fisher Scientific Inc. is the world`s leading science company, with annual sales of more than $25 billion.
Our mission is to enable our customers to make the world healthier, cleaner and safer. Whether our clients accelerate life sciences research, solve complex analytical challenges, improve patient diagnosis and therapy, or increase productivity in their labs, we help them do so. Our global team of more than 75,000 colleagues offers an unparalleled combination of innovative technologies, demonstration customers and pharmaceutical services from our leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, see www.thermofisher.com. The concomitant diagnosis is developed in collaboration with drugs in order to select or exclude groups of patients for the treatment of this specific drug according to their biological properties, which determine the responders and non-responders to the therapy.   The concomitant diagnosis is based on concurrent biomarkers, biomarkers that prospectively help predict a probable reaction or severe toxicity.  The concomitant diagnosis will use the oncomine Precision Assay, To identify patients with non-small cell lung cancer who may benefit from Pyrotinib CARLSBAD, Calif., March 12, 2020 /PRNewswire/ – Thermo Fisher Scientific today signed an agreement with Janssen Biotech, Inc., one of Janssen`s pharmaceutical companies, to develop an oncology companion diagnosis (CDx).